Development of electrochemical immunosensors for HER-1 and HER-2 analysis in serum for breast cancer patients

Simple item page
dc.contributor.authorWignarajah, Shayalini
dc.contributor.authorChianella, Iva
dc.contributor.authorTothill, Ibtisam E.
dc.date.accessioned2023-03-24T15:01:21Z
dc.date.available2023-03-24T15:01:21Z
dc.date.issued2023-03-07
dc.description.abstractIn this work, two human epidermal growth factor receptors, HER-1 and HER-2, were selected as biomarkers to enable the detection of breast cancer. Therefore, two biosensors were developed using gold sensor chips coupled with amperometric detection of the enzyme label horse radish peroxidase (HRP). The biosensors/immunosensors relied on indirect sandwich enzyme-linked immunosorbent assays with monoclonal antibodies (Ab) against HER-1 and HER-2 attached to the sensors to capture the biomarkers. Detection polyclonal antibodies followed by secondary anti-rabbit (for HER-1) and anti-goat (for HER-2) IgG antibody-HRP were then applied for signal generation. In buffer, the developed sensors showed limits of detections (LOD) of 1.06 ng mL−1 and 0.95 ng mL−1 and limits of quantification (LOQ) of 2.1 ng mL−1 and 1.5 ng mL−1 for HER-1 and HER-2, respectively. In 100% (undiluted) serum, LODs of 1.2 ng mL−1 and 1.47 ng mL−1 and LOQs of 1.5 ng mL−1 and 2.1 ng mL−1 were obtained for HER-1 and HER-2, respectively. Such limits of detections are within the serum clinical range for the two biomarkers. Furthermore, gold nanoparticles (AuNP) labelled with secondary anti-rabbit and anti-goat IgG antibody-HRP were then used to enhance the assay signal and increase the sensitivity. In buffers, LODs of 30 pg mL−1 were seen for both sensors and LOQs of 98 pg mL−1 and 35 pg mL−1 were recorded for HER-1 and HER-2, respectively. For HER-2 the AuNPs biosensor was also tested in 100% serum obtaining a LOD of 50 pg mL−1 and a LOQ of 80 pg mL−1. The HER-2 AuNP electrochemical immunosensor showed high specificity with very low cross-reactivity to HER-1. These findings demonstrate that the two developed sensors can enable early detection as well as monitoring of disease progression with a beneficial impact on patient survival and clinical outcomes.en_UK
dc.identifier.citationWignarajah S, Chianella I, Tothill IE. (2023) Development of electrochemical immunosensors for HER-1 and HER-2 analysis in serum for breast cancer patients. Biosensors, Volume 13, Issue 3, March 2023, Article number 355en_UK
dc.identifier.issn2079-6374
dc.identifier.urihttps://doi.org/10.3390/bios13030355
dc.identifier.urihttps://dspace.lib.cranfield.ac.uk/handle/1826/19353
dc.language.isoenen_UK
dc.publisherMDPIen_UK
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectelectrochemical immunosensoren_UK
dc.subjectHER-1 or EGFRen_UK
dc.subjectHER-2en_UK
dc.subjectserumen_UK
dc.subjectamperometryen_UK
dc.subjectgold sensor chipsen_UK
dc.subjectbreast canceren_UK
dc.subjectgold nanoparticleen_UK
dc.titleDevelopment of electrochemical immunosensors for HER-1 and HER-2 analysis in serum for breast cancer patientsen_UK
dc.typeArticleen_UK

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Development_of_electrochemical_immunosensors-2023.pdf
Size:
2.04 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Staff publications (SATM)